BAZ2A and paraganglioma: The survival analysis indicated that increased expression of BAZ2A was linked to a poor prognosis in patients with LIHC, KIRP, pheochromocytoma and paraganglioma (PCPG), and endometrial cancer (UCEC), while reduced expression of BAZ2A was linked to an adverse prognosis in KIRC (Fig. 2A,B).